Reverse DCF
What growth does the market imply for MEDPLUS?
Working backwards from the current price to find the FCF growth assumption baked in.
reasonable
10.6% implied annual FCF growth
The market's growth assumption looks achievable — it is in line with or below what this company has historically delivered.
Current Price
₹865
Historical Growth
20.0%
FCF Yield
3.58%
Price / FCF
27.9x
Plain English
To justify today's price of $865.25, MEDPLUS.NS needs to grow its free cash flow at 10.6% per year for the next 10 years. That is 9.4% slower than its historical growth rate of 20.0%. This looks achievable — the market is not pricing in heroic assumptions. There may be genuine upside if the company executes.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Half implied | 5.3% | ₹537 | -37.9% |
| GDP rate | 10.0% | ₹821 | -5.1% |
| Implied | 10.6% | ₹866 | +0.1% |
| Historical | 20.0% | ₹1,922 | +122.1% |
At Historical Growth Rate
It would take 4 years for MEDPLUS to organically grow into today's price assuming its historical FCF growth of 20.0%.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.